Cagrilintide
Cagrilintide is a long-acting synthetic amylin analog that acts as an agonist at amylin receptors (AMY1, AMY2, AMY3) and the calcitonin receptor. Amylin receptor activation slows gastric emptying, promotes satiety, and reduces food intake via central and peripheral signaling pathways. Its extended half-life supports once-weekly subcutaneous dosing. It is co-formulated with semaglutide as CagriSema; the REDEFINE Phase 3 program evaluates this combination. Both standalone cagrilintide and the combination are investigational.
Appetite or glycemic effects within the first days; full effect accrues over weeks to months alongside titration.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
Long-acting amylin receptor agonist. CagriSema (cagrilintide + semaglutide) Phase 3 (REDEFINE) reported up to 22% weight loss.
Pharmacokinetics
- Half-life (t½)
- 7 d
- Approximate plasma half-life
- Routes
- Subcutaneous
Citations (3)
Last reviewed: 2026-06-14
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Typical Dose Range Observed
Research Protocols
Common DosagesStack Dose
“Investigational; titration mirrors GLP-1”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Reported Uses
- Investigational obesity and weight management (CagriSema with semaglutide, REDEFINE Phase 3)
- Amylin receptor agonism for satiety enhancement and slowed gastric emptying
- Adjunct metabolic therapy for type 2 diabetes glycemic control (investigational)
Key Research Benefits
- Augments GLP-1 weight loss
- Slows gastric emptying
- Reduces cravings
Potential Side Effects
Considerations and Cautions
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- HbA1c: Glycemic efficacy marker; cagrilintide is used with semaglutide (CagriSema).
- Fasting glucose: Tracks glycemic response and hypoglycemia risk in combination therapy.
- Lipid panel / ApoB: Combination incretin/amylin therapy commonly improves atherogenic lipids.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.06 mL on a U-100 syringe
Cagrilintide by goal
Read Cagrilintide's profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.